Evidence Level:Sensitive: D – Preclinical
Title:
Abstract 1549: ACLX-001, a novel BCMA-targeted CAR-T cell therapy that can be activated, silenced, and reprogrammed in vivo with soluble protein adapters in a dose dependent manner
Excerpt:ACLX-001 demonstrated dose- and schedule-dependent in vivo efficacy in disseminated BCMA-expressing tumor models in NSG immunocompromised mice.
DOI:10.1158/1538-7445.AM2021-1549